Home › Scleroderma › North Carolina › Charlotte
Scleroderma clinical trials in Charlotte, NC
3 studies for Scleroderma are looking for participants at sites in and around Charlotte (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RecruitingPhase 1
- Atrium Health Rheumatology-Southpark, Charlotte
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
RecruitingPhase 1/2
- Nkarta Investigational Site, Charlotte
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RecruitingPhase 2
- Artiva Investigational Site Charlotte, Charlotte
- Artiva Investigational Site Charlotte, Charlotte
About Scleroderma
Scleroderma is an autoimmune disease that causes inflammation and thickening in the skin and other areas of the body. The exact cause of scleroderma is unknown.
More about Scleroderma on MedlinePlus
Scleroderma trials in other cities
- New York City, NY11 studies
- Ann Arbor, MI10 studies
- Chicago, IL10 studies
- Houston, TX9 studies
- Boston, MA7 studies
- Durham, NC7 studies
- Los Angeles, CA7 studies
- New Orleans, LA6 studies
- Philadelphia, PA6 studies
- Baltimore, MD6 studies
- Dallas, TX5 studies
- Pittsburgh, PA5 studies
Other studies in Charlotte
- Cancer (all types)27 studies
- Breast Cancer22 studies
- Multiple Myeloma21 studies
- Non-Small Cell Lung Cancer19 studies
- Acute Myeloid Leukemia16 studies
- Obesity16 studies
- Overweight15 studies
- Colorectal Cancer13 studies
- Ovarian Cancer12 studies
- Metastatic Cancer11 studies
- Heart Failure11 studies
- Head and Neck Squamous Cell Carcinoma10 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.